1. Home
  2. VRAX vs ONFO Comparison

VRAX vs ONFO Comparison

Compare VRAX & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VRAX

Virax Biolabs Group Limited

BUY

Current Price

$2.36

Market Cap

2.1M

Sector

Health Care

ML Signal

BUY

Logo Onfolio Holdings Inc.

ONFO

Onfolio Holdings Inc.

HOLD

Current Price

$0.87

Market Cap

202.8K

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
ONFO
Founded
2013
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
202.8K
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
VRAX
ONFO
Price
$2.36
$0.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
26.6K
★ 248.1K
Earning Date
11-20-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $10,730,218.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 36.48
52 Week Low
$0.10
$0.04
52 Week High
$13.19
$6.08

Technical Indicators

Market Signals
Indicator
VRAX
ONFO
Relative Strength Index (RSI) 45.38 42.91
Support Level $0.18 $0.60
Resistance Level $3.01 $1.51
Average True Range (ATR) 0.27 0.08
MACD -0.01 0.01
Stochastic Oscillator 27.69 30.49

Price Performance

Historical Comparison
VRAX
ONFO

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

About ONFO Onfolio Holdings Inc.

Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Pace Generative.

Share on Social Networks: